Abstract 31P
Background
Breast edema is defined as a high signal intensity on T2-weighted magnetic resonance imaging (MRI), and it is an essential image phenotype of breast MRI. The purpose of this study was to investigate the prognostic implication of breast edema on preoperative breast MRI in breast cancer patients.
Methods
We retrospectively analyzed the data of 899 breast cancer patients at a single institution. Patients were divided into the edema-positive group (EPG) and the edema-negative group (ENG) according to the presence of breast edema on preoperative breast MRI. We compared the clinicopathologic characteristics and the survival outcomes between the two groups. A two-sample t-test was used to determine statistical differences between mean ages, and Pearson’s χ2 test was used to determine statistical differences between all the other baseline characteristics. The log-rank test was used to compare the survival curves from Kaplan–Meier estimator. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
Results
There were 399 (44.4%) patients in the EPG and 500 (55.6%) patients in the ENG. Among patients in the EPG, peritumoral, prepectoral, and subcutaneous edemas were present in 387, 130, and 66 patients, respectively. EPG showed significantly higher rates of axillary lymph node metastasis (55.6% vs. 19.2%, p < 0.001) and lymphovascular invasion (LVI) (57.9% vs. 12.6%, p < 0.001) than ENG. Patients in the EPG showed significantly worse overall survival rate (log-rank p < 0.001; HR: 4.83; 95% CI: 2.56-9.11) and recurrence-free survival rate (log-rank p < 0.001; HR: 3.00; 95% CI: 1.94-4.63) than those in the ENG. After adjusting for other variables, breast edema still remained a significant factor affecting overall survival rate regardless of edema type.
Conclusions
Breast edema on preoperative breast MRI is strongly correlated with several clinicopathological features including nodal metastasis and LVI in breast cancer patients. It significantly affects the survival rate and disease recurrence of breast cancer patients. Therefore, detailed descriptions of breast edema in preoperative breast MRI may provide prognosis prediction and more intensive surveillance is needed for breast cancer patients with breast edema.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract